{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091826","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.091086+00:00","generated_at":"2026-05-31T12:06:34.804533+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year","bullets":["NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).","Net income $33.4M ($0.20 EPS) vs $1.1M ($0.01 EPS) in Q2 2023.","NUPLAZID FY guidance raised to $590-610M; DAYBUE lowered to $340-370M.","Total revenue FY guidance revised to $930-980M (from $930M-$1.01B).","Cash and investments $500.9M at June 30, 2024, up from $438.9M at Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091826","json":"https://secwatch.observer/filing/0000950170-24-091826.json","markdown":"https://secwatch.observer/filing/0000950170-24-091826.md","text":"https://secwatch.observer/filing/0000950170-24-091826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024091826/0000950170-24-091826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024091826/acad-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:06:34.804533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}